← Leaderboards
Kellie Bickel
Twinstrand Biosciences, Inc.
$2,555,383
Attributed
$3,124,934
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,124,934 · 1
By mechanism
R44$3,124,934 · 1
Top collaborators
- Christopher S Hourigan1 shared
Most similar at Twinstrand Biosciences, Inc.
Same institution · by research overlap
- Christopher S Hourigan$569,552
Others in their field
Other Rising Stars on “Acute Myeloid Leukemia Cell”
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Saad J. Kenderian · Mayo Clinic Rochester$2,442,317
- Jeevisha Bajaj · University Of Rochester$2,438,184
- Bruno Di Stefano · Baylor College Of Medicine$2,398,360
- Angela Goffredo Fleischman · University Of California-Irvine$2,306,090
- Friederike Herbst-Nowrouzi · University Of Pennsylvania$2,137,320
Research focus
Acute Myeloid Leukemia CellAdoptionAggressive TherapyAllogenicBiochemistryBiological MarkersBloodBone TransplantationCessation Of LifeChemotherapyClinical Decision-MakingClinical RemissionClinical TrialsCohortCollaborationsData SetDetectionDetection LimitDetection MethodDiagnosisDiagnostic ProcedureDisease RemissionDrug DevelopmentAcute Myelocytic Leukemia
Grant awards (2)
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$1,985,831
R44 · FY2025 · CA · contact PI
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$1,139,103
R44 · FY2023 · CA · contact PI